spermidine/spermine N1-acetyl transferase like 1Genealiases: []
Q-omics provides the consensus-scored SATL1 profile across patient tissues and cancer cell-line models. SATL1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, SATL1 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, SATL1 RNA expression shows 10,998 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KICH, KIRC, and GBM as cancer lineages where SATL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SATL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SATL1 survival associations across molecular data types. SATL1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SATL1 RNA expression–survival associations across cancer types. High SATL1 expression shows unfavorable associations in KICH, UCEC, ACC, LIHC and LUAD, but favorable associations in UCS. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for SATL1 RNA expression.
This table summarizes SATL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SATL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SATL1 shows lower tumor expression in KIRC, KIRP and KICH and higher tumor expression in HNSC, LUSC and CHOL. The KIRC box plot shows higher SATL1 RNA expression in normal versus tumor tissue (log2 FC = −0.105, t-test p < 0.001).
This table shows molecular features associated with SATL1 in patient tissues and cancer cell lines. In patient samples, SATL1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SATL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
